Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CCCC

CCCC - C4 Therapeutics Inc Stock Price, Fair Value and News

$2.73-0.02 (-0.73%)
Market Closed

44/100

CCCC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

44/100

CCCC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CCCC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CCCC Price Action

Last 7 days

-10.2%

Last 30 days

49.2%

Last 90 days

10.5%

Trailing 12 Months

35.2%

CCCC RSI Chart

CCCC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CCCC Valuation

Market Cap

266.4M

Price/Earnings (Trailing)

-2.54

Price/Sales (Trailing)

7.41

EV/EBITDA

-1.86

Price/Free Cashflow

-2.68

CCCC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CCCC Fundamentals

CCCC Revenue

Revenue (TTM)

35.9M

Rev. Growth (Yr)

112.79%

Rev. Growth (Qtr)

-1.91%

CCCC Earnings

Earnings (TTM)

-105.0M

Earnings Growth (Yr)

40.75%

Earnings Growth (Qtr)

36.31%

CCCC Profitability

EBT Margin

-291.74%

Return on Equity

-40.92%

Return on Assets

-29.24%

Free Cashflow Yield

-37.28%

CCCC Investor Care

Shares Dilution (1Y)

37.45%

Diluted EPS (TTM)

-1.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202539.8M34.2M30.1M35.9M
202420.9M30.2M34.5M35.6M
202325.5M14.3M18.6M19.9M
202246.0M50.1M48.3M31.1M
202133.8M33.9M34.0M45.8M
202024.3M27.3M30.2M33.2M
201900021.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About C4 Therapeutics Inc

CCCC
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
 CEO
 WEBSITEc4therapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES146

C4 Therapeutics Inc Frequently Asked Questions

CCCC is the stock ticker symbol of C4 Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of C4 Therapeutics Inc is 266.39 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, CCCC's PE ratio (Price to Earnings) is -2.54 and Price to Sales (PS) ratio is 7.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CCCC PE ratio will change depending on the future growth rate expectations of investors.